Trial Details
Not RecruitingBasic Information
| Clinical ID | c2480 |
|---|---|
| Identifier | NL-OMON51097 |
| Trial Title | A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination with Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis_ - AMT-101-203 |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory Bowel Disease Ulcerative Colitis;10017969 |
| Interventions | Both groups are treated with adalimumab for 8 weeks, per standard dose as prescribed 1 group takes 1 tablet of AMT-101 once a day. The other group takes 1 placebo tablet once a day |
Participant Information
| Sponsor | Applied Molecular Tranport Inc. |
|---|---|
| City | - |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | ADULT, ELDER, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | Not Available |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |